Prescription for Gains!
Обновлено
Recursion Pharmaceuticals is building strong bullish momentum, with a gap forming around the $6.00 level. A breakout above the $8.16 resistance would confirm further upside, targeting the $9.99 weekly resistance. This setup provides an attractive risk-to-reward ratio, with downside managed through a stop-loss at $5.49.
In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value.
With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target.
RXRX
In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value.
With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target.
RXRX Сделка активна
Taking some profits here. 
Похожие публикации
Отказ от ответственности
Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.